Multidrug-resistant protein-3 gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small-cell lung carcinoma

Free Radical Biology and Medicine

Volumn 46, Issue 12, 2009, Pages 1650-1657

  Mahaffey, Christopher M ^a,b   Zhang, Hongqiao ^a   Rinna, Alessandra ^a   Holland, William ^b   Mack, Philip C ^b   Forman, Henry Jay ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

4 Hydroxynonenal; A549 cell line; Electrophile response element; Free radicals; H358 cell line; H460 cell line; HBE1 cell line; Keap1; Lung cancer; multidrug resistant proteins; Nrf2

Indexed keywords

4 HYDROXYNONENAL; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MESSENGER RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NRF2;

ARTICLE; BRONCHUS MUCOSA; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; GENE; GENE CONTROL; GENE INDUCTION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LIPID PEROXIDATION; LUNG NON SMALL CELL CANCER; MULTIDRUG RESISTANT PROTEIN 3 GENE; OXIDATIVE STRESS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ALDEHYDES; BASE SEQUENCE; BRONCHI; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; EPITHELIUM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NF-E2-RELATED FACTOR 2; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 67349089075     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2009.03.023     Document Type: Article

References (56)

1. Soria J.C., Lee H.Y., Lee J.I., Wang L., Issa J.P., Kemp B.L., Liu D.D., Kurie J.M., Mao L., and Khuri F.R. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin. Cancer Res. 8 (2002) 1178-1184
2. Sanchez-Cespedes M., Decker P.A., Doffek K.M., Esteller M., Westra W.H., Alawi E.A., Herman J.G., Demeure M.J., Sidransky D., and Ahrendt S.A. Increased loss of chromosome 9p21 but not p16 inactivation in primary non-small cell lung cancer from smokers. Cancer Res. 61 (2001) 2092-2096
3. Young L.C., Campling B.G., Cole S.P., Deeley R.G., and Gerlach J.H. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin. Cancer Res. 7 (2001) 1798-1804
4. Yu S., and Kong A.N. Targeting carcinogen metabolism by dietary cancer preventive compounds. Curr. Cancer Drug Targets 7 (2007) 416-424
5. Itoh K., Mochizuki M., Ishii Y., Ishii T., Shibata T., Kawamoto Y., Kelly V., Sekizawa K., Uchida K., and Yamamoto M. Transcription factor Nrf2 regulates inflammation by mediating the effect of 15-deoxy-Delta(12,14)-prostaglandin J(2). Mol. Cell. Biol. 24 (2004) 36-45
6. Gong P., Stewart D., Hu B., Li N., Cook J., Nel A., and Alam J. Activation of the mouse heme oxygenase-1 gene by 15-deoxy-Delta(12,14)-prostaglandin J(2) is mediated by the stress response elements and transcription factor Nrf2. Antioxid. Redox Signal. 4 (2002) 249-257
7. Rahman I., and Adcock I.M. Oxidative stress and redox regulation of lung inflammation in COPD. Eur. Respir. J. 28 (2006) 219-242
8. Otterbein L.E., and Choi A.M. The saga of leucine zippers continues: in response to oxidative stress. Am. J. Respir. Cell Mol. Biol. 26 (2002) 161-163
9. Motohashi H., and Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol. Med. 10 (2004) 549-557
10. Prestera T., Zhang Y., Spencer S.R., Wilczak C.A., and Talalay P. The electrophile counterattack response: protection against neoplasia and toxicity. Adv. Enzyme Regul. 33 (1993) 281-296
11. Ishii T., Itoh K., Takahashi S., Sato H., Yanagawa T., Katoh Y., Bannai S., and Yamamoto M. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J. Biol. Chem. 275 (2000) 16023-16029
12. Itoh K., Igarashi K., Hayashi N., Nishizawa M., and Yamamoto M. Cloning and characterization of a novel erythroid cell-derived CNC family transcription factor heterodimerizing with the small Maf family proteins. Mol. Cell. Biol. 15 (1995) 4184-4193
13. Itoh K., Chiba T., Takahashi S., Ishii T., Igarashi K., Katoh Y., Oyake T., Hayashi N., Satoh K., Hatayama I., Yamamoto M., and Nabeshima Y. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun. 236 (1997) 313-322
14. Moinova H.R., and Mulcahy R.T. Up-regulation of the human gamma-glutamylcysteine synthetase regulatory subunit gene involves binding of Nrf-2 to an electrophile responsive element. Biochem. Biophys. Res. Commun. 261 (1999) 661-668
15. Wild A.C., Moinova H.R., and Mulcahy R.T. Regulation of gamma-glutamylcysteine synthetase subunit gene expression by the transcription factor Nrf2. J. Biol. Chem. 274 (1999) 33627-33636
16. Alam J., Stewart D., Touchard C., Boinapally S., Choi A.M., and Cook J.L. Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J. Biol. Chem. 274 (1999) 26071-26078
17. Itoh K., Wakabayashi N., Katoh Y., Ishii T., Igarashi K., Engel J.D., and Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 13 (1999) 76-86
18. Itoh K., Wakabayashi N., Katoh Y., Ishii T., O'Connor T., and Yamamoto M. Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles. Genes Cells 8 (2003) 379-391
19. Gerk P.M., and Vore M. Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition. J. Pharmacol. Exp. Ther. 302 (2002) 407-415
20. Borst P., Evers R., Kool M., and Wijnholds J. The multidrug resistance protein family. Biochim. Biophys. Acta 1461 (1999) 347-357
21. Kool M., van der Linden M., de Haas M., Scheffer G.L., de Vree J.M., Smith A.J., Jansen G., Peters G.J., Ponne N., Scheper R.J., Elferink R.P., Baas F., and Borst P. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. USA 96 (1999) 6914-6919
22. Cole S.P., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., Stewart A.J., Kurz E.U., Duncan A.M., and Deeley R.G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258 (1992) 1650-1654
23. Loe D.W., Deeley R.G., and Cole S.P. Biology of the multidrug resistance-associated protein, MRP. Eur. J. Cancer 32A (1996) 945-957
24. Goldstein L.J. MDR1 gene expression in solid tumours. Eur. J. Cancer 32A (1996) 1039-1050
25. Nies A.T., Konig J., Pfannschmidt M., Klar E., Hofmann W.J., and Keppler D. Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int. J. Cancer 94 (2001) 492-499
26. Narasaki F., Oka M., Nakano R., Ikeda K., Fukuda M., Nakamura T., Soda H., Nakagawa M., Kuwano M., and Kohno S. Human canalicular multispecific organic anion transporter (cMOAT) is expressed in human lung, gastric, and colorectal cancer cells. Biochem. Biophys. Res. Commun. 240 (1997) 606-611
27. Schaub T.P., Kartenbeck J., Konig J., Spring H., Dorsam J., Staehler G., Storkel S., Thon W.F., and Keppler D. Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J. Am. Soc. Nephrol. 10 (1999) 1159-1169
28. Nooter K., de la Riviere G.B., Klijn J., Stoter G., and Foekens J. Multidrug resistance protein in recurrent breast cancer. Lancet 349 (1997) 1885-1886
29. Nooter K., Burger H., and Stoter G. Multidrug resistance-associated protein (MRP) in haematological malignancies. Leuk. Lymphoma 20 (1996) 381-387
30. Chan H.S., Lu Y., Grogan T.M., Haddad G., Hipfner D.R., Cole S.P., Deeley R.G., Ling V., and Gallie B.L. Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein. Cancer Res. 57 (1997) 2325-2330
31. Ota E., Abe Y., Oshika Y., Ozeki Y., Iwasaki M., Inoue H., Yamazaki H., Ueyama Y., Takagi K., Ogata T., et al. Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. Br. J. Cancer 72 (1995) 550-554
32. Kool M., de Haas M., Scheffer G.L., Scheper R.J., van Eijk M.J., Juijn J.A., Baas F., and Borst P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 57 (1997) 3537-3547
33. Belinsky M.G., Bain L.J., Balsara B.B., Testa J.R., and Kruh G.D. Characterization of MOAT-C and MOAT-D, new members of the MRP/cMOAT subfamily of transporter proteins. J. Natl. Cancer Inst. 90 (1998) 1735-1741
34. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., and Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39 (1999) 361-398
35. Konig J., Rost D., Cui Y., and Keppler D. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 29 (1999) 1156-1163
36. Mottino A.D., Hoffman T., Jennes L., and Vore M. Expression and localization of multidrug resistant protein mrp2 in rat small intestine. J. Pharmacol. Exp. Ther. 293 (2000) 717-723
37. Lockhart A.C., Tirona R.G., and Kim R.B. Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol. Cancer Ther. 2 (2003) 685-698
38. Deeley R.G., Westlake C., and Cole S.P. Transmembrane transport of endo-and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol. Rev. 86 (2006) 849-899
39. Hirohashi T., Suzuki H., and Sugiyama Y. Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J. Biol. Chem. 274 (1999) 15181-15185
40. Rost D., Mahner S., Sugiyama Y., and Stremmel W. Expression and localization of the multidrug resistance-associated protein 3 in rat small and large intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 282 (2002) G720-726
41. Young L.C., Campling B.G., Voskoglou-Nomikos T., Cole S.P., Deeley R.G., and Gerlach J.H. Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response. Clin. Cancer Res. 5 (1999) 673-680
42. Tirumalai R., Rajesh Kumar T., Mai K.H., and Biswal S. Acrolein causes transcriptional induction of phase II genes by activation of Nrf2 in human lung type II epithelial (A549) cells. Toxicol. Lett. 132 (2002) 27-36
43. Zhang C.Y., Feng Y.X., Yu Y., Sun W.J., Bai J., Chen F., and Fu S.B. The molecular mechanism of resistance to methotrexate in mouse methotrexate-resistant cells by cancer drug resistance and metabolism SuperArray. Basic Clin. Pharmacol. Toxicol. 99 (2006) 141-145
44. Strohmaier H., Hinghofer-Szalkay H., and Schaur R.J. Detection of 4-hydroxynonenal (HNE) as a physiological component in human plasma. J. Lipid Mediat. Cell Signaling 11 (1995) 51-61
45. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog. Lipid Res. 42 (2003) 318-343
46. Parola M., Bellomo G., Robino G., Barrera G., and Dianzani M.U. 4-Hydroxynonenal as a biological signal: molecular basis and pathophysiological implications. Antioxid. Redox Signal. 1 (1999) 255-284
47. Zhang H., Liu H., Iles K.E., Liu R.M., Postlethwait E.M., Laperche Y., and Forman H.J. 4-Hydroxynonenal induces rat gamma-glutamyl transpeptidase through mitogen-activated protein kinase-mediated electrophile response element/nuclear factor erythroid 2-related factor 2 signaling. Am. J. Respir. Cell Mol. Biol. 34 (2006) 174-181
48. Gradhand U., Tegude H., Burk O., Eichelbaum M., Fromm M.F., and Konig J. Functional analysis of the polymorphism -211C>T in the regulatory region of the human ABCC3 gene. Life Sci. 80 (2007) 1490-1494
49. Zhang H., Court N., and Forman H.J. Submicromolar concentrations of 4-hydroxynonenal induce glutamate cysteine ligase expression in HBE1 cells. Redox Rep. 12 (2007) 101-106
50. Singh A., Misra V., Thimmulappa R.K., Lee H., Ames S., Hoque M.O., Herman J.G., Baylin S.B., Sidransky D., Gabrielson E., Brock M.V., and Biswal S. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med. 3 (2006) e420
51. Lau A., Villeneuve N.F., Sun Z., Wong P.K., and Zhang D.D. Dual roles of Nrf2 in cancer. Pharmacol. Res. 58 (2008) 262-270
52. Wang X.J., Sun Z., Villeneuve N.F., Zhang S., Zhao F., Li Y., Chen W., Yi X., Zheng W., Wondrak G.T., Wong P.K., and Zhang D.D. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 29 (2008) 1235-1243
53. Hashimoto T., Tokuchi Y., Hayashi M., Kobayashi Y., Nishida K., Hayashi S., Ishikawa Y., Tsuchiya S., Nakagawa K., Hayashi J., and Tsuchiya E. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. Cancer Res. 59 (1999) 5572-5577
54. Lai S., Perng R., and Hwang J. p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells. J. Biomed. Sci. 7 (2000) 64-70
55. Muredda M., Nunoya K., Burtch-Wright R.A., Kurz E.U., Cole S.P., and Deeley R.G. Cloning and characterization of the murine and rat Mrp1 promoter regions. Mol. Pharmacol. 64 (2003) 1259-1269
56. Sullivan G.F., Yang J.M., Vassil A., Yang J., Bash-Babula J., and Hait W.N. Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells. J. Clin. Invest. 105 (2000) 1261-1267